CJC/IPA Protocol
GHRH/GHRP Combination · Growth Hormone Optimization
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
Overview
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.
Sustained GH patterns may accelerate muscle repair between exercise sessions.
GH optimization helps maintain muscle during caloric restriction or aging.
Growth hormone promotes lipolysis while supporting lean tissue maintenance.
Enhanced GH patterns may improve glucose and fat utilization.
Evening GH peaks align with deeper, more restorative sleep patterns.
Sustained GH elevation supports skin elasticity and connective tissue health.
Growth hormone supports tissue repair and recovery from exercise or injury.
Enhanced collagen synthesis supports joint and connective tissue integrity.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Peptide combination (GHRH analog + GHS)
- Typical dose
- 200-300mcg of each peptide (CJC-1295 and Ipamorelin)
- Frequency
- Once daily, preferably in the evening
- Cycle length
- 8-12 weeks on
- Storage
- Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Molecular data
- Type
- Peptide combination (GHRH analog + GHS)
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| General Health Optimization | SubQ | 200mcg each (0.2mL if 1mg/mL) | Once daily |
| Performance Enhancement | SubQ | 250mcg each (0.25mL if 1mg/mL) | Once daily |
| Recovery Optimization | SubQ | 300mcg each (0.3mL if 1mg/mL) | Once daily |
| Conservative Approach | SubQ | 150mcg each (0.15mL if 1mg/mL) | 5 days per week |
Interactions
Both affect GH pathways; monitor for excessive GH elevation and insulin sensitivity changes.
No known interactions; different mechanisms (GH optimization vs. tissue repair signaling).
GH affects insulin sensitivity; diabetic users require glucose monitoring and insulin adjustments.
Redundant mechanisms may cause excessive GH suppression of natural pulsatile release.
Space 4+ hours from GH secretagogues due to absorption and metabolic interactions.
May blunt GH response; higher doses or alternative timing may be necessary.
Quality checklist
- ✓Standard format labeling: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin'
- ✓1:1 ratio maintenance between peptides for optimal effects
- ✓Clear reconstitution without particles or cloudiness
- ✓Certificate of Analysis with individual peptide purities
- ✓Proper cold chain with cold packs and immediate refrigeration
- !Format selection: Beginners prefer separate vials for tolerance testing
- !Blended format offers convenience but limits dose adjustment
- !Combination protocols lack peer-reviewed clinical validation
- ×Damaged packaging or missing refrigeration
- ×Heat exposure during shipping
- ×Lack of Certificate of Analysis documentation
What to expect
Safety
- Water retention and joint swelling
- Carpal tunnel syndrome (numbness/tingling)
- Mild blood glucose elevation
- Injection site irritation with improper rotation
- Persistent joint pain or swelling indicating fluid retention
- Significant blood glucose changes or diabetic control issues
- Unusual fatigue, lethargy, or mood deterioration
- Injection site infections or persistent reactions
- Numbness or tingling in hands/feet
- Signs of accelerated tumor growth if cancer history exists
- Cancer history or active malignancy
- Severe diabetes requiring tight glucose control
- Carpal tunnel syndrome or nerve compression disorders
FAQ
Why do people combine CJC-1295 and Ipamorelin instead of using them separately?
CJC-1295 and Ipamorelin target GH secretion through complementary mechanisms—CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin receptors—creating synergistic effects greater than either peptide alone. Ipamorelin uniquely avoids cortisol elevation, making the combination particularly effective and tolerable.
Can I use the CJC/IPA protocol if I have a history of diabetes?
CJC/IPA combinations require caution with diabetes history due to GH's insulin-antagonistic effects. Both peptides elevate growth hormone which can impair glucose tolerance. Medical supervision and regular blood glucose monitoring are essential before starting, especially with the continuous GH elevation this protocol provides.
What's the advantage of Ipamorelin over GHRP-6 in this combination?
Ipamorelin is selective for GH release and does NOT elevate cortisol or prolactin even at high doses, whereas GHRP-6 causes significant appetite stimulation and potential cortisol elevation. For the CJC/IPA protocol, Ipamorelin provides cleaner GH stimulation without the side effects of broader GHRP peptides.
Should CJC/IPA be dosed together in the same injection or separately?
Both approaches work—some use blended vials containing both peptides at a 1:1 ratio, while others inject separately at the same or different sites. Blended vials offer convenience but allow less flexibility to adjust individual peptide doses, while separate vials let you customize ratios if needed.
References
- 1Ipamorelin, the first selective growth hormone secretagogueRaun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998
Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.
reviewPubMed 9849822 ↗ - 2Ghrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptorsCunha SR, Mayo KE · Endocrinology · 2002
GHS potentiate GHRH-induced cAMP in a dose-dependent manner requiring co-expression of both receptors, providing the cellular basis for GHRH/GHRP synergy.
reviewPubMed 12446584 ↗ - 3Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy AdultsTeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhore R · Journal of Clinical Endocrinology & Metabolism · 2006
Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.
human-pilotPubMed 16352683 ↗ - 4Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone AnalogIonescu M, Frohman LA · Journal of Clinical Endocrinology & Metabolism · 2006
Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.
reviewPubMed 17018654 ↗